Understanding Inflammatory Heterogeneity in NSAID-Exacerbated Respiratory Disease.
作者信息
Turner Justin H, Kato Atsushi
机构信息
Department of Otolaryngology-Head and Neck Surgery, University of Alabama-Birmingham, Birmingham, Ala.
Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill.
出版信息
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2914-2916. doi: 10.1016/j.jaip.2024.07.035. Epub 2024 Aug 19.
Abstract
摘要
相似文献
1
Understanding Inflammatory Heterogeneity in NSAID-Exacerbated Respiratory Disease.理解非甾体抗炎药加重的呼吸道疾病中的炎症异质性。
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2914-2916. doi: 10.1016/j.jaip.2024.07.035. Epub 2024 Aug 19.
2
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.非甾体抗炎药加重的呼吸道疾病患者的下呼吸道炎症异质性。
J Allergy Clin Immunol. 2021 Apr;147(4):1269-1280. doi: 10.1016/j.jaci.2020.08.007. Epub 2020 Aug 15.
3
The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).氧化应激产物在非甾体抗炎药加重的呼吸道疾病（N-ERD）中的作用。
Adv Pharmacol. 2023;97:423-444. doi: 10.1016/bs.apha.2022.12.002. Epub 2023 Jan 10.
4
Sex, Ethnicity, Body Mass Index, and Environmental Exposures Associated With NSAID-Exacerbated Respiratory Disease Symptom Sequence.性别、种族、体重指数与环境暴露与 NSAID 加重的呼吸道疾病症状序列相关。
J Allergy Clin Immunol Pract. 2023 Dec;11(12):3662-3669.e2. doi: 10.1016/j.jaip.2023.07.035. Epub 2023 Aug 2.
5
Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi.生物制剂在 NSAID-ERD 中的疗效：从鼻腔到支气管的联合航空。
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2917-2932. doi: 10.1016/j.jaip.2024.09.021. Epub 2024 Sep 27.
6
NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.NSAID-ERD 综合征：从预防、早期诊断和新治疗靶点中看到的新希望。
Curr Allergy Asthma Rep. 2020 Mar 14;20(4):10. doi: 10.1007/s11882-020-00905-9.
7
Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease.支气管上皮细胞转录组显示非甾体抗炎药加重的呼吸道疾病患者哮喘的内型异质性。
J Allergy Clin Immunol. 2023 Apr;151(4):953-965. doi: 10.1016/j.jaci.2022.10.029. Epub 2022 Nov 14.
8
Updates on the Natural History and Clinical Characteristics of NSAID-ERD.非甾体抗炎药相关的内镜阴性消化性疾病的自然史和临床特征的最新研究进展。
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2889-2896. doi: 10.1016/j.jaip.2024.07.013. Epub 2024 Jul 20.
9
Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?非甾体抗炎药加重的呼吸道疾病（N-ERD）中的单克隆抗体或阿司匹林脱敏治疗？
Front Allergy. 2023 Apr 12;4:1080951. doi: 10.3389/falgy.2023.1080951. eCollection 2023.
10
Inheritance of NSAID-Exacerbated Respiratory Disease.非甾体抗炎药加重性呼吸道疾病的遗传方式
Otolaryngol Head Neck Surg. 2023 Mar;168(3):540-543. doi: 10.1177/01945998221102085. Epub 2023 Jan 29.
引用本文的文献
1
Clinical and mechanistic advancements in aspirin exacerbated respiratory disease.阿司匹林加重呼吸道疾病的临床与机制进展
J Allergy Clin Immunol. 2025 May;155(5):1411-1419. doi: 10.1016/j.jaci.2025.03.006. Epub 2025 Mar 18.
本文引用的文献
1
Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease.支气管上皮细胞转录组显示非甾体抗炎药加重的呼吸道疾病患者哮喘的内型异质性。
J Allergy Clin Immunol. 2023 Apr;151(4):953-965. doi: 10.1016/j.jaci.2022.10.029. Epub 2022 Nov 14.
2
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.度普利尤单抗在阿司匹林加重性呼吸道疾病中的快速和持续疗效及其作用机制。
J Allergy Clin Immunol. 2022 Aug;150(2):415-424. doi: 10.1016/j.jaci.2022.04.007. Epub 2022 Apr 20.
3
Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.鼻黏液炎症谱作为阿司匹林加重性呼吸系统疾病中鼻息肉再生生物标志物的效用
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1644-1645.e1. doi: 10.1016/j.jaip.2022.03.021. Epub 2022 Apr 8.
4
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.度普利尤单抗治疗未得到控制的伴有鼻息肉的重度慢性鼻-鼻窦炎和 NSAID-ERD 临床诊断患者的疗效和安全性：两项随机安慰剂对照 3 期临床试验的结果。
Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1.
5
Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.预测阿司匹林治疗反应的生物标志物在阿司匹林加重性呼吸道疾病中的应用。
Clin Exp Allergy. 2021 Aug;51(8):1046-1056. doi: 10.1111/cea.13886. Epub 2021 May 11.
6
Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.阿司匹林加重的呼吸道疾病中的炎症异质性。
J Allergy Clin Immunol. 2021 Apr;147(4):1318-1328.e5. doi: 10.1016/j.jaci.2020.11.001. Epub 2020 Nov 12.
7
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.非甾体抗炎药加重的呼吸道疾病患者的下呼吸道炎症异质性。
J Allergy Clin Immunol. 2021 Apr;147(4):1269-1280. doi: 10.1016/j.jaci.2020.08.007. Epub 2020 Aug 15.
8
Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis.通过潜在类别分析确定的非甾体抗炎药加重的呼吸疾病亚表型。
Allergy. 2020 Apr;75(4):831-840. doi: 10.1111/all.14141. Epub 2020 Jan 28.
9
Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease.慢性鼻-鼻窦炎中的细胞因子。在嗜酸性粒细胞增多和阿司匹林诱发的呼吸道疾病中的作用。
Am J Respir Crit Care Med. 2015 Sep 15;192(6):682-94. doi: 10.1164/rccm.201412-2278OC.
10
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.阿司匹林敏感性鼻-鼻窦炎-哮喘：一项阿司匹林治疗的双盲交叉研究。
J Allergy Clin Immunol. 1984 Apr;73(4):500-7. doi: 10.1016/0091-6749(84)90361-0.
Zotero 插件